Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Intestinal Fistula Surgery Workup

  • Author: Neelu Pal, MD; Chief Editor: John Geibel, MD, DSc, MSc, MA  more...
 
Updated: Sep 18, 2015
 

Laboratory Studies

Although laboratory tests do not help diagnose or confirm the presence of intestinal fistulas, they are important for defining the patient’s clinical condition and guiding treatment.

A complete blood count (CBC) should be obtained. An elevated white blood cell (WBC) count suggests associated infection. Abscesses, soft-tissue infection adjacent to an enterocutaneous fistula, bacteremia, or bloodstream infection may be present. Elderly patients or those who are severely nutritionally depleted may not manifest an elevated WBC count as an indicator of infection.

An electrolyte panel is helpful. Electrolyte imbalances and dehydration are common in patients with high-output enterocutaneous fistulas because of intestinal fluid loss. Hypokalemia, hypochloremia, and metabolic alkalosis are observed in patients with high-output gastric fistulas. Patients with pancreatic and small-bowel fistulas have associated hyponatremia, hypokalemia, and metabolic acidosis. Nephroenteric fistulas are often associated with decreased renal function, which manifests as elevated creatinine and blood urea nitrogen (BUN) and a reduced glomerular filtration rate (GFR).

Serum albumin levels are used to predict fistula closure and mortality. In one study, a serum albumin level higher than 3.5 mg/dL was associated with no mortality, whereas a level below 2.5 mg/dL was associated with a mortality of 42%. Higher levels of short-turnover proteins (eg, serum transferrin, prealbumin, retinol-binding protein) are used to predict fistula closure. A serum transferrin level higher than 200 mg/dL is associated with a higher rate of fistula closure and a lower mortality and vice versa.

Patients who are bacteremic or septic have positive blood culture findings. Results of blood culture are used to direct antibiotic therapy to the appropriate organisms.

In a patient with an enterovesical fistula, urine analysis and culture are both are useful for initial confirmation of the diagnosis, as well as for directing antibiotic therapy to the appropriate organisms.

Next

Imaging Studies

Computed tomography (CT) allows identification as well as guided drainage of associated abscesses or fluid collection. CT with oral contrast can also identify the site of the fistula. Gastric, duodenal, and proximal small-bowel fistulas can be readily identified. The presence or absence of distal bowel obstruction can be revealed; if intraluminal contrast passes distal to the fistula site, then distal obstruction is unlikely. Passage of the oral contrast, as well as the early presence of contrast within the colonic lumen, can demonstrate the gastrocolic fistula tract. The presence of periaortic inflammation, air collection, or fluid collection characterizes aortoenteric fistulas.

Fistulography is performed to confirm and define the location of an enterocutaneous fistula. Closed-suction drainage catheters are placed under radiologic guidance to drain abscesses or fluid collections. If the drainage contents are clearly enteric, the area is allowed to drain adequately for 7-10 days. This period allows a tract to form. The patient is stabilized with correction of electrolyte imbalances and administration of antibiotics. Water-soluble contrast is injected via the drainage catheter under fluoroscopy or during CT. Intraluminal passage of contrast confirms the presence and defines the origin of the fistula. A complete contrast study of the gastrointestinal (GI) tract should follow fistulography.

Small-bowel follow-through contrast radiography often identifies enteroenteric fistulas in patients with Crohn disease and chronic radiation enteritis. The study is obtained to evaluate nonspecific complaints of abdominal pain, cramping, diarrhea, and anorexia. All of these symptoms and signs are attributable both to the primary disease and to internal fistulas.

Previous
Next

Other Tests

After oral administration of activated charcoal, the presence of charcoal granules in the discharge fluid also confirms the presence of an enterocutaneous fistula. The appearance of charcoal particles in urine or vaginal discharge after oral administration confirms an enterovesical fistula or an enterovaginal fistula, respectively.

After oral administration of methylene blue, emergence of the dye thorough an incision, a drain, or a skin defect confirms the presence of an enterocutaneous fistula. Similarly, this test has been used to confirm the presence of an enterovesical fistula and an enterovaginal fistula. Although the use of methylene blue has been described in the surgical literature as a method to detect intraoperative and postoperative anastomotic leaks, it has been curtailed because of reports of associated patient deaths. For this reason, methylene blue is not recommended as a means to detect or confirm the presence of a fistula in situations where other investigative modalities can be used.

Previous
Next

Diagnostic Procedures

Diagnostic procedures may include the following:

  • Upper GI endoscopy - The presence of bleeding and inflammatory thickening of the wall of the distal duodenum in a patient with an aortic prosthetic graft indicates an aortoenteric fistula
  • Cystoscopy - Enterovesical fistulas are often identified on cystoscopic examination; the presence of an area of inflammation and active purulent or intestinal content drainage confirms the diagnosis
Previous
 
 
Contributor Information and Disclosures
Author

Neelu Pal, MD General Surgeon

Neelu Pal, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, Society of American Gastrointestinal and Endoscopic Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

David L Morris, MD, PhD, FRACS Professor, Department of Surgery, St George Hospital, University of New South Wales, Australia

David L Morris, MD, PhD, FRACS is a member of the following medical societies: British Society of Gastroenterology

Disclosure: Received none from RFA Medical for director; Received none from MRC Biotec for director.

Chief Editor

John Geibel, MD, DSc, MSc, MA Vice Chair and Professor, Department of Surgery, Section of Gastrointestinal Medicine, and Department of Cellular and Molecular Physiology, Yale University School of Medicine; Director, Surgical Research, Department of Surgery, Yale-New Haven Hospital; American Gastroenterological Association Fellow

John Geibel, MD, DSc, MSc, MA is a member of the following medical societies: American Gastroenterological Association, American Physiological Society, American Society of Nephrology, Association for Academic Surgery, International Society of Nephrology, New York Academy of Sciences, Society for Surgery of the Alimentary Tract

Disclosure: Received royalty from AMGEN for consulting; Received ownership interest from Ardelyx for consulting.

Additional Contributors

Brian J Daley, MD, MBA, FACS, FCCP, CNSC Professor and Program Director, Department of Surgery, Chief, Division of Trauma and Critical Care, University of Tennessee Health Science Center College of Medicine

Brian J Daley, MD, MBA, FACS, FCCP, CNSC is a member of the following medical societies: American Association for the Surgery of Trauma, Eastern Association for the Surgery of Trauma, Southern Surgical Association, American College of Chest Physicians, American College of Surgeons, American Medical Association, Association for Academic Surgery, Association for Surgical Education, Shock Society, Society of Critical Care Medicine, Southeastern Surgical Congress, Tennessee Medical Association

Disclosure: Nothing to disclose.

References
  1. Barnes SA, Lillemoe KA. Small Intestinal Fistulas. Zuidema G, Yeo CJ. Shackelford's Surgery of the Alimentary Tract. 5. USA: W. B. Saunders; 2002. 5: 29.

  2. Minei JP, Champine JG. Gastointestinal Fistulas. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 8. Canada: Saunders; 2006. 1: 25.

  3. Williams LJ, Zolfaghari S, Boushey RP. Complications of enterocutaneous fistulas and their management. Clin Colon Rectal Surg. 2010 Sep. 23(3):209-20. [Medline]. [Full Text].

  4. Binenbaum SJ, Goldfarb MA. Inadvertent enterotomy in minimally invasive abdominal surgery. JSLS. 2006 Jul-Sep. 10(3):336-40. [Medline].

  5. Campos AC, Andrade DF, Campos GM, et al. A multivariate model to determine prognostic factors in gastrointestinal fistulas. J Am Coll Surg. May/1999. 188(5):483-90. [Medline].

  6. Evenson AR, Fischer JE. Current management of enterocutaneous fistula. J Gastrointest Surg. 2006 Mar. 10(3):455-64. [Medline].

  7. Lloyd DA, Gabe SM, Windsor AC. Nutrition and management of enterocutaneous fistula. Br J Surg. 2006 Sep. 93(9):1045-55. [Medline].

  8. Alivizatos V, Felekis D, Zorbalas A. Evaluation of the effectiveness of octreotide in the conservative treatment of postoperative enterocutaneous fistulas. Hepatogastroenterology. 2002 Jul-Aug. 49(46):1010-2. [Medline].

  9. Amiot A, Setakhr V, Seksik P, Allez M, Treton X, De Vos M, et al. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol. 2014 Sep. 109 (9):1443-9. [Medline].

  10. Ciccocioppo R, Gallia A, Sgarella A, Kruzliak P, Gobbi PG, Corazza GR. Long-Term Follow-Up of Crohn Disease Fistulas After Local Injections of Bone Marrow-Derived Mesenchymal Stem Cells. Mayo Clin Proc. 2015 Jun. 90 (6):747-55. [Medline].

  11. Campos AC, Meguid MM, Coelho JC. Factors influencing outcome in patients with gastrointestinal fistula. Surg Clin North Am. 1996 Oct. 76(5):1191-8. [Medline].

  12. Chitale VR. Enterocutaneous fistulas treated successfully by a turnover flap from surrounding tissue reinforced by musculocutaneous flaps and other local flaps. Plast Reconstr Surg. 1993 May. 91(6):1171-2. [Medline].

  13. Davis M, Dere K, Hadley G. Options for managing an open wound with draining enterocutaneous fistula. J Wound Ostomy Continence Nurs. 2000 Mar. 27(2):118-23. [Medline].

  14. Dearlove JL. Skin care management of gastrointestinal fistulas. Surg Clin North Am. 1996 Oct. 76(5):1095-109. [Medline].

  15. DePeyster FA. Simple device to control corrosive excretions from upper digestive tract fistulas. Surg Gynecol Obstet. 1957 Mar. 104(3):375-6. [Medline].

  16. Foster CE 3rd, Lefor AT. General management of gastrointestinal fistulas. Recognition, stabilization, and correction of fluid and electrolyte imbalances. Surg Clin North Am. 1996 Oct. 76(5):1019-33. [Medline].

  17. Heys SD, Walker LG, Smith I, et al. Enteral nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials. Ann Surg. 1999 Apr. 229(4):467-77. [Medline].

  18. Kuvshinoff BW, Brodish RJ, McFadden DW, et al. Serum transferrin as a prognostic indicator of spontaneous closure and mortality in gastrointestinal cutaneous fistulas. Ann Surg. 1993 Jun. 217(6):615-22; discussion 622-3. [Medline].

  19. Lynch AC, Delaney CP, Senagore AJ, et al. Clinical outcome and factors predictive of recurrence after enterocutaneous fistula surgery. Ann Surg. 2004 Nov. 240(5):825-31. [Medline].

  20. Mayberry JC, Burgess EA, Goldman RK, et al. Enterocutaneous fistula and ventral hernia after absorbable mesh prosthesis closure for trauma: the plain truth. J Trauma. 2004 Jul. 57(1):157-62; discussion 163-3. [Medline].

  21. Moorthy K, Shaul T, Foley RJ. The laparoscopic management of benign bowel fistulas. JSLS. 2004 Oct-Dec. 8(4):356-8. [Medline].

  22. Pokala N, Delaney CP, Brady KM, et al. Elective laparoscopic surgery for benign internal enteric fistulas: a review of 43 cases. Surg Endosc. 2005 Feb. 19(2):222-5. [Medline].

  23. Present DH. Crohn's fistula: current concepts in management. Gastroenterology. 2003 May. 124(6):1629-35. [Medline].

  24. Regan JP, Salky BA. Laparoscopic treatment of enteric fistulas. Surg Endosc. 2004 Feb. 18(2):252-4. [Medline].

  25. Ricart E, Sandborn WJ. Infliximab for the treatment of fistulas in patients with Crohn'S disease. Gastroenterology. 1999 Nov. 117(5):1247-8. [Medline].

  26. Rubelowsky J, Machiedo GW. Reoperative versus conservative management for gastrointestinal fistulas. Surg Clin North Am. 1991 Feb. 71(1):147-57. [Medline].

  27. Sarfeh IJ, Jakowatz JG. Surgical treatment of enteric 'bud' fistulas in contaminated wounds. A riskless extraperitoneal method using split-thickness skin grafts. Arch Surg. Sep/1992. 127(9):1027-30. [Medline].

  28. Schafer M, Lauper M, Krahenbühl L. Trocar and Veress needle injuries during laparoscopy. Surg Endosc. 2001 Mar. 15(3):275-80. [Medline].

  29. Schuster MR, Crummy AB, Wojtowycz MM, et al. Abdominal abscesses associated with enteric fistulas: percutaneous management. J Vasc Interv Radiol. 1992 May. 3(2):359-63. [Medline].

  30. Soeters PB, Ebeid AM, Fischer JE. Review of 404 patients with gastrointestinal fistulas. Impact of parenteral nutrition. Ann Surg. 1979 Aug. 190(2):189-202. [Medline].

  31. Steinke W, Zellweger R. Richter's hernia and Sir Frederick Treves: an original clinical experience, review, and historical overview. Ann Surg. 2000 Nov. 232(5):710-8. [Medline].

  32. Suriyapa C, Anderson MC. A simple device to control drainage from enterocutaneous fistulas. Surgery. 1971 Sep. 70(3):455-8. [Medline].

  33. Tachi M, Hirabayashi S. Enterocutaneous fistula treated with a fasciocutaneous turnover flap. Ann Plast Surg. 2002 May. 48(5):554-6. [Medline].

  34. Thomas HA. Radiologic investigation and treatment of gastrointestinal fistulas. Surg Clin North Am. 1996 Oct. 76(5):1081-94. [Medline].

  35. Torres AJ, Landa JI, Moreno-Azcoita M, et al. Somatostatin in the management of gastrointestinal fistulas. A multicenter trial. Arch Surg. 1992 Jan. 127(1):97-9; discussion 100. [Medline].

  36. Truong S, Bohm G, Klinge U, et al. Results after endoscopic treatment of postoperative upper gastrointestinal fistulas and leaks using combined Vicryl plug and fibrin glue. Surg Endosc. 2004 Jul. 18(7):1105-8. [Medline].

  37. Van Der Krabben AA, Dijkstra FR, et al. Morbidity and mortality of inadvertent enterotomy during adhesiotomy. Br J Surg. 2000 Apr. 87(4):467-71. [Medline].

  38. Wolfe BM, Keltner RM, Willman VL. Intestinal fistula output in regular, elemental, and intravenous alimentation. Am J Surg. 1972 Dec. 124(6):803-6. [Medline].

 
Previous
Next
 
Classification of fistulas.
Management algorithm for intestinal fistulas.
Predictive factors for spontaneous closure and mortality associated with fistulas.
Postoperative enterocutaneous fistula. Fistula forms as a result of partial or complete intestinal anastomotic disruption and associated resultant abscess.
Congenital patent omphalomesenteric duct resulting in an enterocutaneous fistula.
Enterovesical fistula.
Nephroenteric fistula.
Enterovaginal fistula.
Aortoenteric fistula demonstrating a direct connection between the intestinal lumen (typically the duodenum) and the prosthetic graft.
Aortoenteric fistula that forms through erosion of a periprosthetic graft infection into the intestinal lumen.
Enterocutaneous fistula output is controlled through placement of a soft-sump drain into the cutaneous opening of the fistula tract. The sump drain is connected to low suction, and the fistula opening and drain are contained within an ileostomy bag. An additional drain is placed within the bag and to continuous suction to keep the bag empty and to minimize the contact of surrounding skin with enteric contents.
Bypass of fistulous bowel loops that are densely adherent within the pelvic cavity by creation of an anastomosis between the divided afferent limb and the transverse colon.
Bypass of a densely adherent fistula by anastomosis of afferent and efferent limbs of intestine in continuity. This is an ineffective method of bypass, since the enteric contents continue to flow into the fistula tract.
A densely adherent or unresectable fistula is bypassed by dividing both afferent and efferent intestinal loops and reanastomosing the divided ends to restore intestinal continuity. The fistula tract is essentially isolated from the enteric stream. If a longer loop of bowel is bypassed, the divided ends can be exteriorized.
Enterocutaneous fistula.
Enterocutaneous fistula.
Resected enterocutaneous fistula, embedded in surrounding inflammatory tissue and skin.
Stapled closure of intestinal lumen to restore intestinal continuity following resection of enterocutaneous fistula.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.